Neurodegenerative Drugs
Neurodegenerative Drugs Market by Drug Class (Cholinesterase Inhibitors, Decarboxylase Inhibitors, Dopamine Agonist), Indication (Alzheimer’s Disease, Dementia, Huntington’s Disease), Sales Channel - Global Forecast 2024-2030
360iResearch Analyst
Want to know more about the neurodegenerative drugs market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[182 Pages Report] The Neurodegenerative Drugs Market size was estimated at USD 41.84 billion in 2023 and expected to reach USD 45.91 billion in 2024, at a CAGR 8.67% to reach USD 74.93 billion by 2030.

Neurodegenerative drugs encompass therapeutic agents designed to manage and treat progressive neurological disorders, including conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, spinal muscular atrophy, and Huntington's disease. The rising global prevalence of these diseases, driven by an aging population, highlights the urgent need for effective treatments. These drugs are utilized in various settings such as hospitals, specialty clinics, and home care, reflecting their versatility and importance in ongoing patient care. Crucial end-users include pharmaceutical companies developing new drugs, research institutes conducting innovative treatments, academic institutions engaged in early-stage research, and government and non-profit organizations funding research initiatives. Key growth factors driving this market include an aging global population, technological advancements enhancing treatment efficacy, increased funding and research investments from both the government and private sector, and rising awareness leading to earlier diagnosis and treatment. However, challenges include high development costs, stringent regulatory environments, limited knowledge of disease mechanisms, side effects and safety concerns, market saturation, and economic barriers restricting access to treatment. Notable opportunities exist in areas such as personalized medicine, biological and gene therapies, and collaborative R&D initiatives. Innovations in gene therapy, stem cell research, digital health technologies, and biomarker development are crucial for the market's progress.

Regional Insights

The market for neurodegenerative drugs is robust, driven by significant R&D investments and advanced healthcare infrastructure in the United States, supported by government initiatives. In the European nations, pivotal players, including Germany, France, and the United Kingdom (UK), emphasize collaborative research funded by entities such as the European Medicines Agency (EMA), facilitating drug approvals. Regionally, Asia-Pacific shows rising incidents of neurodegenerative diseases, with a growing focus on biotechnology. Japan faces a substantial demographic challenge, necessitating advanced healthcare and R&D initiatives through the Japan Agency for Medical Research and Development (AMED). China's market growth is propelled by an aging population and government-led healthcare reforms prioritizing biotechnology. Canada benefits from governmental support and public-private partnerships, contributing significantly to research advancements. India's expanding market is driven by increasing awareness and cost-effective drug manufacturing.

The United States, through the Food and Drug Administration (FDA), employs stringent approval processes while offering expedited pathways for critical treatments. The European Medicines Agency (EMA) emphasizes high safety standards and has a centralized procedure for obtaining EU-wide authorization. Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and China's National Medical Products Administration (NMPA) are aligning their regulations with international standards, promoting faster drug approval and innovation.

Neurodegenerative Drugs Market
To learn more about this report, request a free PDF copy
Market Dynamics

The market dynamics represent an ever-changing landscape of the Neurodegenerative Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Rising awareness about neurological disorders and need of early diagnosis & treatment
    • Increasing investment in healthcare sector to improve healthcare accessibility
  • Market Restraints
    • Complexities & risk associated with the neurodegenerative treatment
  • Market Opportunities
    • Ongoing research & development activities for neurodegenerative drugs
    • Increasing number of drug approval by regulatory authorities
  • Market Challenges
    • Severe side effects associated with the consumption of neurodegenerative drugs
Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Neurodegenerative Drugs Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Neurodegenerative Drugs Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Neurodegenerative Drugs Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Neurodegenerative Drugs Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Neurodegenerative Drugs Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Neurodegenerative Drugs Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Neurodegenerative Drugs Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Neurodegenerative Drugs Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Neurodegenerative Drugs Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Neurodegenerative Drugs Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The Neurodegenerative Drugs Market Research Report published by 360iResearch has been a game-changer for our ongoing research and development activities for neurodegenerative drugs. Prior to this, we faced significant challenges in identifying market trends and potential opportunities. The report provided us with valuable insights and actionable strategies that helped us fine-tune our R&D efforts. Specifically, the detailed analysis of market dynamics and competitive landscape enabled us to make informed decisions, leading to accelerated development timelines and more effective resource allocation. Overall, we are extremely satisfied with the positive impact this report has had on our operations.
Abbott Laboratories
FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Neurodegenerative Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Neurodegenerative Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Neurodegenerative Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

As a leading pharmaceutical company, we at Lupin Limited were facing significant challenges in addressing the rising awareness about neurological disorders and the growing need for early diagnosis and treatment. The Neurodegenerative Drugs Market Research Report published by 360iResearch provided us with invaluable insights and actionable strategies that we implemented with great success. The report's detailed analysis of market trends, patient demographics, and emerging therapies helped us realign our product development pipeline and marketing efforts. One of the most significant benefits was the identification of key market segments and potential areas for growth, allowing us to make informed decisions that positively impacted our organization's operations. Overall, our experience with the 360iResearch report has been immensely satisfying and instrumental in achieving our strategic goals.
Lupin Limited
Key Company Profiles

The report delves into recent significant developments in the Neurodegenerative Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Lupin Limited, Aquinnah Pharmaceuticals, Merck & Co., Inc., Theravance Biopharma, AbbVie Inc., Amneal Pharmaceuticals, Inc., Pfizer, Inc., AZTherapies, Inc., Biogen Inc., Johnson & Johnson Services, Inc., Bausch Health Companies Inc., Denali Therapeutics Inc., GlaxoSmithKline PLC, Sanofi S.A., Orion Corporation, Boehringer Ingelheim International GmbH, Kyowa Kirin International plc, Prevail Therapeutics Inc. by Eli Lilly and Company, ACADIA Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Novartis AG, H. Lundbeck A/S, and UCB S.A..

Neurodegenerative Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Neurodegenerative Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Cholinesterase Inhibitors
    • Decarboxylase Inhibitors
    • Dopamine Agonist
    • Immunomodulators
  • Indication
    • Alzheimer’s Disease
    • Dementia
    • Huntington’s Disease
    • Motor Neurone Disease
    • Parkinson’s Disease
    • Prion Disease
    • Spinal Muscular Atrophy
  • Sales Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Before leveraging the Neurodegenerative Drugs Market Research Report by 360iResearch, we faced significant challenges in navigating the complex regulatory landscape for drug approvals. The report provided us with invaluable insights and actionable strategies that revolutionized our approach. Specifically, the detailed analysis on market trends and regulatory requirements helped us increase our number of drug approvals. This, in turn, has significantly boosted our operational efficiency and market presence. We are exceedingly satisfied with the profound impact this report has had on our organization.
Aquinnah Pharmaceuticals
This research report offers invaluable insights into various crucial aspects of the Neurodegenerative Drugs Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Neurodegenerative Drugs Market, by Drug Class
  7. Neurodegenerative Drugs Market, by Indication
  8. Neurodegenerative Drugs Market, by Sales Channel
  9. Americas Neurodegenerative Drugs Market
  10. Asia-Pacific Neurodegenerative Drugs Market
  11. Europe, Middle East & Africa Neurodegenerative Drugs Market
  12. Competitive Landscape
  13. Competitive Portfolio
  14. List of Figures [Total: 22]
  15. List of Tables [Total: 382]
  16. List of Companies Mentioned [Total: 25]
Understanding the Ongoing Research and Development for Neurodegenerative Drugs
August 8, 2023
Understanding the Ongoing Research and Development for Neurodegenerative Drugs
Neurodegenerative diseases are a group of medical conditions that affect the functioning of the nervous system and lead to the progressive degeneration of nerve cells. They include diseases such as Alzheimer's, Parkinson's, and Huntington's disease, among others. However, there is ongoing research and development of new drugs for neurodegenerative diseases, and this blog post will explore these drugs' latest developments and prospects.

Understanding Neurodegenerative Diseases:

Before delving into the research and development of drugs for neurodegenerative diseases, it is important to understand them. These diseases typically develop over a long period, with symptoms gradually worsening as the condition progresses.

Current Treatments for Neurodegenerative Diseases:

As mentioned earlier, there is no cure for neurodegenerative diseases. Treatments aim to manage symptoms such as tremors, cognitive decline, and mobility problems. Current treatments include medication, physiotherapy, and surgery.

Ongoing Research and Drug Development:

Research into neurodegenerative diseases has been ongoing for decades, with scientists and researchers looking for ways to halt or reverse the progression of these diseases. Several promising drugs are currently being developed, including those that target the accumulation of abnormal proteins in the brain, those that reduce inflammation and oxidative stress, and those that protect against nerve cell death.

Future Prospects:

The future of neurodegenerative drugs looks promising, with several clinical trials underway for potential drugs. One of the potential drugs under development is aducanumab, a drug that targets the amyloid protein in the brain and has shown promising results in clinical trials. However, even with promising results, it may take several years before these drugs become widely available to treat neurodegenerative diseases.

Importance of Continued Research:

The development of effective treatments for neurodegenerative diseases is crucial, given the increasing incidence of these conditions and their devastating impact on individuals and families. Continued research and development are vital in finding ways to halt or reverse the progression of these conditions, providing hope and improving the quality of life.

Neurodegenerative diseases are complex conditions with significant impacts on individuals and society. Although current treatments can only alleviate symptoms, ongoing research and drug development provide hope for future treatments that could effectively halt or reverse the progression of these diseases. Continued research is necessary to ensure promising drugs become available to those affected by these conditions.

Frequently Asked Questions
  1. How big is the Neurodegenerative Drugs Market?
    Ans. The Global Neurodegenerative Drugs Market size was estimated at USD 41.84 billion in 2023 and expected to reach USD 45.91 billion in 2024.
  2. What is the Neurodegenerative Drugs Market growth?
    Ans. The Global Neurodegenerative Drugs Market to grow USD 74.93 billion by 2030, at a CAGR of 8.67%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.